Literature DB >> 22460964

Factors associated with discordance between absolute CD4 cell count and CD4 cell percentage in patients coinfected with HIV and hepatitis C virus.

Mark W Hull1, Kathleen Rollet, Adefowope Odueyungbo, Sahar Saeed, Martin Potter, Joseph Cox, Curtis Cooper, John Gill, Marina B Klein.   

Abstract

BACKGROUND: Liver cirrhosis has been associated with decreased absolute CD4 cell counts but preserved CD4 cell percentage in human immunodeficiency virus (HIV)-negative persons. We evaluated factors associated with discordance between the absolute CD4 cell count and the CD4 cell percentage in a cohort of patients coinfected with HIV and hepatitis C virus (HCV).
METHODS: Baseline data from 908 participants in a prospective, Canadian, multisite cohort of individuals with HIV-HCV coinfection were analyzed. Absolute CD4 cell count and CD4 cell percentage relationships were evaluated. We defined low and high discordance between absolute CD4 cell count/CD4 cell percentage relationships as CD4 cell percentages that differed from the expected CD4 cell percentage, given the observed absolute CD4 cell count, by ±7 percentage points; we defined very low and very high discordance as differences of ±14 percentage points. Factors associated with high or very high discordance, including either end-stage liver disease or aspartate transaminase to platelet ratio index (APRI) of >1.5, were analyzed using multivariate logistic regression models and compared to groups with concordant and low discordant results.
RESULTS: High/very high discordance was seen in 31% (n = 286), while 35% (n = 321) had concordant values. Factors associated with very high discordance at baseline included history of end-stage liver disease (adjusted odds ratio [aOR], 6.52; 95% confidence interval [CI], 2.27-18.67) and APRI of >1.5 (aOR 4.69; 95% CI, 1.64-13.35). Compared with those with detectable HCV RNA, those who cleared HCV spontaneously were less likely to have very high discordance.
CONCLUSIONS: Discordance between absolute CD4 cell count and CD4 cell percentage is common in an HIV/HCV-coinfected population and is associated with advanced liver disease and ongoing HCV replication.

Entities:  

Mesh:

Year:  2012        PMID: 22460964     DOI: 10.1093/cid/cis289

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  10 in total

Review 1.  Advances in the management of HIV/HCV coinfection.

Authors:  Mattias Mandorfer; Philipp Schwabl; Sebastian Steiner; Thomas Reiberger; Markus Peck-Radosavljevic
Journal:  Hepatol Int       Date:  2016-01-12       Impact factor: 6.047

2.  [Not Available].

Authors:  Mark Hull; Pierre Giguère; Marina Klein; Stephen Shafran; Alice Tseng; Pierre Côté; Marc Poliquin; Curtis Cooper
Journal:  Can J Infect Dis Med Microbiol       Date:  2014       Impact factor: 2.471

3.  CD4/CD8 ratio is a promising candidate for non-invasive measurement of liver fibrosis in chronic HCV-monoinfected patients.

Authors:  Thijs Feuth; Debbie van Baarle; Karel J van Erpecum; Peter D Siersema; Andy I M Hoepelman; Joop E Arends
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-01-22       Impact factor: 3.267

Review 4.  Hepatitis C virus infection in the human immunodeficiency virus infected patient.

Authors:  Louise Nygaard Clausen; Lene Fogt Lundbo; Thomas Benfield
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

5.  CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults.

Authors:  Mark Hull; Marina Klein; Stephen Shafran; Alice Tseng; Pierre Giguère; Pierre Côté; Marc Poliquin; Curtis Cooper
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

6.  The Implications of Low Absolute CD4 Counts in Patients With Cirrhosis and Human Immunodeficiency Virus.

Authors:  Timothy Sullivan
Journal:  Open Forum Infect Dis       Date:  2016-03-29       Impact factor: 3.835

7.  CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment.

Authors:  Mark Hull; Stephen Shafran; Alex Wong; Alice Tseng; Pierre Giguère; Lisa Barrett; Shariq Haider; Brian Conway; Marina Klein; Curtis Cooper
Journal:  Can J Infect Dis Med Microbiol       Date:  2016-07-04       Impact factor: 2.471

8.  Seroprevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) among human immunodeficiency virus (HIV)-infected patients in an HBV endemic area in Brazil.

Authors:  Claudinei Mesquita da Silva; Leyde Daiane de Peder; Alessandra Michele Guelere; Josana Dranka Horvath; Eraldo Schunk Silva; Jorge Juarez Vieira Teixeira; Dennis Armando Bertolini
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

9.  Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV-Coinfected Patients in Clinical Care.

Authors:  Carmine Rossi; Jim Young; Valérie Martel-Laferrière; Sharon Walmsley; Curtis Cooper; Alexander Wong; M John Gill; Marina B Klein
Journal:  Open Forum Infect Dis       Date:  2019-02-13       Impact factor: 3.835

10.  Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada?

Authors:  Urvi Rana; Matt Driedger; Paul Sereda; Shenyi Pan; Erin Ding; Alex Wong; Sharon Walmsley; Marina Klein; Deborah Kelly; Mona Loutfy; Rejean Thomas; Stephen Sanche; Abigail Kroch; Nima Machouf; Marie-Helene Roy-Gagnon; Robert Hogg; Curtis L Cooper
Journal:  BMC Infect Dis       Date:  2019-11-21       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.